SPRO earnings analysis
What we found in SPRO's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The filing reflects a major strategic transition: Utebzi received FDA approval and Spero secured $105.0 million of royalty financing, while the company shifted its development focus to SP001. Liquidity improved materially, with $50.8 million of cash at June 30, 2026 and management expecting funding into the second half of 2029, but the company still reported a $9.6 million quarterly net loss and remains highly dependent on GSK commercialization and the single clinical-stage candidate SP001. The filing extract does not provide sufficient current-quarter revenue, EPS, margin, segment, or cash-flow detail to calculate those metrics or compare them with the prior period and prior year.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Utebzi Receives FDA Approval
- The FDA approved Utebzi (tebipenem pivoxil) on June 17, 2026, providing Spero with an approved product through its GSK collaboration.
- Secured $105M Royalty Financing
- Spero and its affiliates entered into a $105.0 million non-recourse, non-dilutive royalty financing transaction with HCRx in July 2026.
- Liquidity Extends Into 2029
- The company reported cash and cash equivalents of $50.8 million as of June 30, 2026, and expects available funding, including the July financing proceeds, to support operations into the second half of 2029.
- New SP001 Development Strategy
- Spero in-licensed SP001 from Innovent on July 8, 2026, and currently expects to advance it into a Phase 2 IgG4-RD trial in the second quarter of 2027, subject to FDA clearance of the U.S. IND.
- Losses Remain Significant
- The company recorded a net loss of $9.6 million for the three months ended June 30, 2026, and a net loss of $16.8 million for the six months ended June 30, 2026.
- SEC Company Investigation Concluded
- The SEC notified Spero on January 20, 2026 that it had concluded its investigation and did not intend to recommend an enforcement action against the company at that time.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Single-Candidate Clinical Concentration
- SP001 is the company's only product candidate currently in clinical development following termination of SPR206 and SPR720. Any safety, efficacy, development or regulatory problem affecting SP001 could significantly harm the business.
- Limited Utebzi Economic Participation
- Although Utebzi was approved on June 17, 2026, Spero's royalty and milestone receipts are limited to 35% of GSK Proceeds arising after the HCRx notes are paid in full. The company therefore remains dependent on GSK commercialization and on Utebzi generating sufficient proceeds.
- FDA Acceptance of China Data
- SP001 relies in part on Innovent data from a Phase 1b study conducted in China, and the company states that the FDA may not accept foreign clinical data. A May 2026 draft report also proposed barring FDA consideration of covered clinical data generated at sites in China and certain other countries.
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management stated that cash and cash equivalents as of June 30, 2026, together with July 2026 royalty-financing proceeds, are expected to fund operating expenses and capital expenditures into the second half of 2029; SP001 is currently expected to enter a Phase 2 trial in the second quarter of 2027, subject to FDA clearance of the U.S. IND.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 13, 2026
- Spero Therapeutics reported strong Q4 2026 results with revenue surging to $41 million, marking a significant increase from just $14 million in the previous quarter. Gross margin returned to positivity at 100%, and EPS…
- 10-K · March 26, 2026
- Spero has re‑focused on a single program (tebipenem HBr) and its GSK collaboration after terminating SPR206 and SPR720; GSK resubmitted an NDA in December 2025 that was accepted with a PDUFA date of June 18, 2026.…
- 10-Q · November 13, 2025
- Q3 2025 results reflect a much smaller operating footprint after program reprioritizations: revenue was $5.44M and net loss narrowed to $7.38M (EPS $(0.13)) versus revenue $13.47M and loss $17.15M in Q3 2024. Management…
- 10-Q · May 13, 2025
- Spero reported Q1 revenue of $5,874 (in thousands) versus $9,267 in Q1 2024, a 36.6% year-over-year decline, and recorded a net loss of $13,866 (in thousands) or $(0.25) per share. Operating loss widened to $(14,731)…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing SPRO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever